$54.48
-0.07-0.13%
In chiusura: -
$54.99
0.510.94%
After hour: 5:18 PM EDT
Comments
Loading...
Guidance e previsioni
BioMarin Pharmaceutical fornisce indicazioni su EPS e ricavi futuri, offrendo agli investitori informazioni su quanto la società prevede di guadagnare nei prossimi periodi.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
08/04/2025 | BMRN | BioMarin Pharmaceutical | FY | 2025 | $4.40 | $4.55 | $3.86 | $3.13B | $3.20B | $3.15B | |
05/16/2025 | BMRN | Biomarin Pharmaceutical | FY | 2025 | $4.20 | $4.40 | $4.31 | $3.10B | $3.20B | $3.14B | |
05/01/2025 | BMRN | Biomarin Pharmaceutical | FY | 2025 | $4.20 | $4.40 | $4.30 | $3.10B | $3.20B | $3.14B | |
02/19/2025 | BMRN | Biomarin Pharmaceutical | FY | 2025 | $4.20 | $4.40 | $4.16 | $3.10B | $3.20B | $3.10B | |
10/29/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $3.25 | $3.35 | $2.07 | $2.79B | $2.83B | $2.80B | |
09/04/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $3.10 | $3.25 | $2.04 | $2.75B | $2.83B | $2.80B | |
09/04/2024 | BMRN | Biomarin Pharmaceutical | FY | 2027 | — | — | — | $4.00B | $4.00B | — | |
08/05/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $3.10 | $3.25 | $2.87 | $2.75B | $2.83B | $2.74B | |
04/24/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $2.75 | $2.95 | $1.65 | $2.70B | $2.80B | $2.77B | |
02/22/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $2.60 | $2.80 | $1.96 | $2.70B | $2.80B | $2.83B | |
11/01/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.90 | $2.05 | $1.02 | $2.39B | $2.47B | $2.45B | |
07/31/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.85 | $2.10 | $1.02 | $2.38B | $2.50B | $2.46B | |
04/26/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.80 | $2.05 | $0.95 | $2.38B | $2.50B | $2.46B | |
02/27/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.80 | $2.05 | $1.61 | $2.38B | $2.50B | $2.58B | |
10/26/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.06B | $2.16B | $2.12B | |
08/03/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.06B | $2.16B | $2.11B | |
04/27/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.05B | $2.15B | $2.10B | |
02/23/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.05B | $2.15B | $2.14B | |
10/27/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.82B | $1.88B | $1.85B | |
07/28/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.79B | $1.88B | $1.82B | |
04/29/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.75B | $1.85B | $1.81B | |
02/25/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.75B | $1.85B | $1.91B |
FAQ
Qual è la guidance più recente per BioMarin Pharmaceutical (BMRN)?
Le ultime previsioni per BioMarin Pharmaceutical (BMRN) sono state riportate il agosto 4, 2025 per l'intero anno 2025. L'azienda ha fornito una previsione di utili per azione nell'intervallo da $4.40 a $4.55, rispetto all'EPS stimato di $3.86. Inoltre, BioMarin Pharmaceutical ha previsto ricavi tra $3.13B e $3.20B per il trimestre.
Sfoglia guidance e previsioni su tutte le azioni.